Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Treatment Considerations for Transgender PWH

Listen as Dr Michelle D. Collins-Ogle shares some of the key considerations for ART management for transgender PWH, including providing care within a gender-affirmative care model, considering drug–drug interactions between hormone therapy and ART, and addressing barriers to engagement and retention in care.
Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS
Released: May 26, 2022

In this episode, Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, explores key considerations for transgender people with HIV (PWH).

Listen as she gives perspectives on:

  • Department of Health and Human Services (DHHS) guideline recommendations for transgender PWH
  • Providing HIV care within a gender-affirmative care model, including discussion of strategies, barriers, and facilitators
  • Gender-affirmative hormone therapy options
  • Drug–drug interaction potential between gender-affirmative hormone therapy and antiretroviral therapy
  • Recommended laboratory monitoring while receiving gender-affirming hormone therapy
  • The cascade of care for transgender PWH and barriers to engagement and retention in care

Information on this Educational Activity

Faculty

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS

Assistant Professor of Pediatrics
Division of Pediatric Infectious Diseases
Pediatric and Adolescent HIV
Children’s Hospital at Montefiore
Pediatric Hospital of Albert Einstein
College of Medicine
Bronx, New York

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

International expert panel discusses clinic-level aspects of incorporating long-acting ART into HIV care in this podcast from Clinical Care Options (CCO)

person default Yvonne Gilleece, MB BCh, BAO Cristina Mussini, MD Babafemi Taiwo, MBBS Darrell H. S. Tan, MD, FRCPC, PhD Released: August 2, 2022

Dr Darcy Wooten and Clinical Care Options (CCO): Data are emerging on strategies to manage ART-associated weight gain and metabolic complications

Darcy Wooten, MD Released: August 1, 2022

Considerations for switching to long-acting CAB + RPV in appropriate patients with HIV, from Dr Darcy Wooten and Clinical Care Options (CCO)

Darcy Wooten, MD Released: July 22, 2022

Clinical Care Options (CCO) expert audio: international panel discusses switching patients to long-acting injectable ART for HIV treatment

person default Yvonne Gilleece, MB BCh, BAO Cristina Mussini, MD Babafemi Taiwo, MBBS Darrell H. S. Tan, MD, FRCPC, PhD Released: July 14, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings